Search Results

You are looking at 1 - 9 of 9 items for :

  • sustainability x
  • Anatomy and Physiology x
Clear All
Open access

Floriana Elvira Ionică, Rigas F. Nikolaos and Florica Popescu

dementia in older patients with type 2 diabetes mellitus. JAMA 301: 1565-1572, 2009. 8. Vilsboll T, Rosenstock J, Yki-Jarvinen H et al. Sitagliptin, a selective DPP-4 inhibitor, improves glycemic control when added to insulin, with or without metformin, in patients with type 2. Diabetes 58[Suppl 1]: 588, 2009. 9. Fonseca V, Baron M, Shao Q, Dejager S. Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Horm Metab Res 40: 427-430, 2008

Open access

Cristina Văduva, Simona Popa, Maria Moţa and Eugen Moţa

fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295: 1681-1687, 2006. 8. Monnier L, Colette C, Owens DR. Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it? J Diabetes Sci Technol 2: 1094-1100, 2008. 9. Monnier L, Colette C. Glycemic variability: should we and can we prevent it ? Diabetes Care 31: S150- S154, 2008. 10. Nelson RG, Tuttle KR. The new KDOQI clinical practice guidelines and clinical practice

Open access

Seyed Mansour Alamshah, Aliasghar Hemmati and Zahra Nazari

: 1504-1509, 2001. 4. Williams JZ, Abumrad N, Barbul A. Effect of a specialized amino acid mixture on human collagen deposition. Ann Surg 236: 369-374, 2002. 5. Zheng XP, Ding Y, Zheng MZ. Effect of zhuhuang frost on wound hydroxyl-proline level after anal operation. Zhongguo Zhong Xi Yi Jie He Za Zhi. 21: 272-273, 2001. 6. Sakallioglu AE, Yagmurlu A, Dindar H, Hasirci N, Renda N, Deveci MS. Sustained local application of low-dose epidermal growth factor on steroid-inhibited colonic wound healing. J Pediatr Surg 39: 591

Open access

Mihaela Vlad, Bogdan Timar, Adrian Vlad and Romulus Timar

Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. NEJM 329: 977-986, 1993 16. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy. The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. JAMA 290: 2159

Open access

Bogdan Timar and Oana Albai

(7): 1486-1490, 2006. 9. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group . Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 290(16): 2159-2167, 2003. 10. Ray KK, Seshasai SR, Wijesuriya S et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes

Open access

Ariel Florenţiu and Radu Lichiardopol

, Bullock J et al. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol 47: 633-641, 2007. 13. D’Alessio DA, Denney AM, Hermiller LM et al. Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes. J Clin Endocrinol Metab 94: 81-88, 2009. 14. Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon

Open access

Cristian Guja and Andrada Mihai

multiple dosing. Clin Pharmacokinet 50: 65–74, 2011. 12. LaRue S, Malloy J. Evaluation of the dual-chamber pen design for the injection of exenatide once weekly for the treatment of type 2 diabetes. J Diabetes Sci Technol 9: 815–821, 2015. 13. Buse JB, Drucker DJ, Taylor KL et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 33: 1255–1261, 2010. 14. Wysham CH, Philis-Tsimikas A, Klein EJ et al. DURATION-1 extension in patients with T2D: efficacy and tolerability of exenatide

Open access

Bogdan-Mircea Mihai, Cristina Mihaela Lăcătuşu, Elena-Daniela Grigorescu and Gina Eosefina Botnariu

initiate phase 3a development of oral semaglutide, a once-daily oral GLP-1 analogue. Accessed at: https://www.novonordisk.com/bin/getPDF.1947638.pdf 13. Henry RR, Rosenstock J, Logan D, Alessi T, Luskey K, Baron MA. Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes. J Diabetes Complications 28: 393-398, 2014. 14. Henry RR, Rosenstock J, Logan DK, Alessi TR, Luskey K, Baron MA. Randomized trial of continuous

Open access

Simona Georgiana Popa, Adina Popa and Maria Moţa

Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 290: 2159-2167, 2003. 30. Del Prato S, Felton AM, Munro N et al. Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. Int J Clin Pract 59: 1345-1355, 2005. 31. Bianchi C, Del Prato S. La terapia insulinica nel diabete mellito di tipo 2. In: Bolli G, Del Prato S, Riccardi G., editors. La